

July 29, 2024

Company SanBio Co., Ltd.

name: (Code: 4592 TSE Growth)

Name of Keita Mori, Representative Director and

representative: President


For inquiries, Yoshihiro Kakutani, Corporate Officer of

contact: Management Administration

(Phone: 03-6264-3481)

<u>Partial Revision to the "Notice Concerning Notice of Allowance of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the US"</u>

SanBio Co., Ltd. hereby provides on this matter as per the attached document.





Partial Revision to the "Notice Concerning Notice of Allowance of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the US"

SanBio Co., Ltd. (Head office: Tokyo, Representative Director and President: Keita Mori) hereby announce a partial revision to our today's disclosure, "Notice Concerning Notice of Allowance of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the US" as follows.

The corrected parts are underlined.

[Before correction]

Patent application number: US 17/674,856

[After correction]

Patent application number: US 17/664,856

For more information, contact:

SanBio Co., Ltd.

Management Administration Email: info@sanbio.com